Project Grant R43AI188690
Award Date 8/8/25
Completion Date 7/31/27
Dollars Obligated $299K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Worcester, MA 01605, USA
Similar Awards
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $683,995.00 to fund research to develop novel therapeutics targeting human cytomegalovirus (CMV) infections. The research focuses on characterizing the mechanism of action and optimizing a series of N-arylpyrimidinamine (NAPA) compounds that demonstrated potent anti-CMV activity in a high-throughput screening assay....
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), awarded a $762,983 Project Grant to The Medical College of Wisconsin, Inc. (MCW) to support research focused on "Discovery and Development of Novel HCMV Inhibitors". The goal of this project is to develop a new class of inhibitors that act through a novel viral target, the helicase-primase (H/P) complex, to address the limited...
- The Icahn School of Medicine at Mount Sinai received a $696,985 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports the development of novel antiviral agents targeting the early stage of human cytomegalovirus (CMV) replication. This research aims to identify inhibitors that can limit the propagation and spread of CMV, which is a leading cause of birth defects and...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $232,415 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, Davis. The goal of this 2-year award, with a period of performance from November 2024 to October 2026, is to develop a highly potent monoclonal antibody that can neutralize the cytomegalovirus (CMV)-encoded interleukin-10 (IL-10) protein, in order to prevent primary CMV infection and reduce the...
- The National Institute of Allergy and Infectious Diseases (NIAID), through its Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $1,135,986 Project Grant to Northwestern University. The grant, effective January 1, 2025, aims to identify cellular and molecular targets for developing tissue/cell-specific strategies to prevent cytomegalovirus (CMV) reactivation and improve outcomes in kidney transplant recipients. The research will investigate the role of...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $683,927 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Icahn School of Medicine at Mount Sinai (ISMMS) to develop and characterize broadly neutralizing human monoclonal antibodies (mAbs) as potential therapeutics to inhibit human cytomegalovirus (CMV) infection and dissemination. The key objectives of this 1-year project are to: 1) identify neutralizing CMV mAbs targeting...
- This Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), is focused on the development of novel benzyl-piperidine antifungal agents to treat intractable Mucorales infections. The $299,946 award to Microbiotix, Inc., a clinical-stage biopharmaceutical company in Worcester, MA, aims to chemically optimize a lead series of benzyl-piperidine compounds to improve their...
- This $832,910 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to identify immune factors associated with risk of cytomegalovirus (CMV) disease in orthotopic liver transplant recipients. The University of Washington is the primary awardee, with the goal of developing a clinically useful measure of CMV disease risk to guide prevention efforts. The research focuses on...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $682,879 to The Medical College of Wisconsin, Inc. to conduct research on the impacts of human cytomegalovirus (HCMV) infection on human neural tissue development. The project aims to (1) define the transcriptional and cellular disruptions to developing human neural cells caused by HCMV infection, (2) determine...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research CFDA program (93.855), will support research to investigate the differences in immune responses between infants with congenital cytomegalovirus (cCMV) infection and those with postnatal CMV infection. The $598,664 award, with a performance period from May 2, 2025 to April 30, 2029, will enable the Research Institute at Nationwide Children's...